Barclays Issues Positive Forecast for Certara (NASDAQ:CERT) Stock Price

Key Points

• Barclays raised its Certara price target from $9 to $12 but kept an “equal weight” rating; the new target is roughly in line with the stock’s $12.01 price.
• Analyst sentiment is mixed: Certara has an overall “Hold” rating and an average price target of $9.73, though TD Cowen and KeyCorp have issued Buy and Overweight ratings, respectively.
• Third-quarter revenue of $94.9 million exceeded estimates and EPS of $0.09 met consensus, but revenue fell 9.3% year over year. Certara’s 2026 revenue forecast of $427.2 million–$431.4 million was well above analyst consensus.

Certara (NASDAQ:CERT - Get Free Report) had its price objective boosted by stock analysts at Barclays from $9.00 to $12.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently has an "equal weight" rating on the stock. Barclays's price target indicates a potential downside of 0.07% from the stock's current price.

A number of other research firms have also commented on CERT. TD Cowen raised their price objective on shares of Certara from $9.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, October 13th. UBS Group reaffirmed a "neutral" rating and set a $13.00 price objective on shares of Certara in a research note on Friday. Weiss Ratings lowered shares of Certara from a "sell (d)" rating to a "sell (d-)" rating in a report on Thursday, October 8th. Finally, KeyCorp increased their target price on shares of Certara from $9.00 to $12.00 and gave the stock an "overweight" rating in a research note on Friday, October 16th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Certara currently has an average rating of "Hold" and an average target price of $9.73.

Certara Price Performance

CERT traded down $0.17 during trading on Friday, reaching $12.01. 1,032,012 shares of the company were exchanged, compared to its average volume of 3,392,518. The company's 50-day moving average is $9.26 and its two-hundred day moving average is $7.33. The company has a market cap of $1.83 billion, a price-to-earnings ratio of -26.75 and a beta of 1.30. The company has a quick ratio of 2.55, a current ratio of 2.55 and a debt-to-equity ratio of 0.30. Certara has a 12-month low of $4.45 and a 12-month high of $12.31.

Certara (NASDAQ:CERT - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $0.09 earnings per share for the quarter, meeting analysts' consensus estimates of $0.09. The business had revenue of $94.90 million during the quarter, compared to analyst estimates of $92.01 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%. The company's quarterly revenue was down 9.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.14 EPS. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. Research analysts forecast that Certara will post 0.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Deutsche Bank AG bought a new stake in Certara during the second quarter worth about $803,000. Haveli Investment Management LLC purchased a new position in shares of Certara in the 2nd quarter worth about $48,470,000. Granite Investment Partners LLC purchased a new position in shares of Certara in the 1st quarter worth about $2,130,000. Bank of New York Mellon Corp bought a new position in shares of Certara during the 2nd quarter valued at about $4,788,000. Finally, BlackRock Inc. bought a new position in shares of Certara during the 2nd quarter valued at about $123,259,000. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara News Roundup

Here are the key news stories impacting Certara this week:

• Positive Sentiment: Certara forecast 2026 revenue of $427.2 million to $431.4 million, well above the $380.9 million analyst consensus. Its EPS outlook of $0.31 to $0.34 also reaches or exceeds the $0.31 consensus midpoint, signaling improved expectations. Why Did Certara Shares Climb After Its Latest Update?
• Positive Sentiment: Third-quarter revenue of $94.9 million topped analysts’ $92.01 million estimate, and earnings of $0.09 per share met or exceeded consensus estimates cited in reports. Coverage highlighted software revenue growth reaching double digits for the first time in two years, alongside expanding margins. Certara Reports Third Quarter 2026 Financial Results Q3 Earnings Call Highlights
• Neutral Sentiment: Certara appointed Grant Peterson as chief product officer. The reports did not indicate an immediate financial impact from the leadership change. Certara Reports Third Quarter 2026 Financial Results
• Negative Sentiment: Despite beating revenue expectations, quarterly revenue fell 9.3% year over year, and EPS declined from $0.14 to $0.09. Those comparisons may temper optimism about the results. Certara Tops Q3 Earnings and Revenue Estimates

About Certara

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.